within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01F_MacrolidesLincosamidesAndStreptogramins.J01FA13_Dirithromycin;

model Dirithromycin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.1,
    Cl = 5.555555555555556e-06,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.2,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.008333333333333333,
    Tlag = 15.0);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dirithromycin</td></tr><tr><td>ATC code:</td><td>J01FA13</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>200</td><td>L</td></tr>
    <tr><td>clearance:</td><td>20</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dirithromycin is a semi-synthetic macrolide antibiotic of the erythromycin family. It is a prodrug that is hydrolyzed to its active form, 9(S)-erythromycyclamine, after oral administration. It was used for the treatment of respiratory tract infections and other infections caused by susceptible bacteria, but is not widely marketed or approved in many countries today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following a single oral dose.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01FA13 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dirithromycin;
